Molecular therapy of primary liver carcinoma Monika Pazgan-Simon, Sylwia Serafińska, Krzysztof Simon Medical Science Review - Hepatologia 2009; 9 69-72 aaICID: 902247
Article type: Review article
IC™ Value: 3.04
Abstract provided by Publisher
Primary liver cancer usually develops in a liver changed by chronic disease. In spite of monitoring, cancer diagnosis is unclear, especially in cirrhotic patients. Most have advanced tumor stage and effective therapy, such as surgery, transplantation, or ablation, is not possible. Systemic chemotherapy or radiotherapy is also unsuccessful among these patients. Recently, however, some results of molecular targeted therapy (MTT) based on hepatocarcinogenic inhibition pathways show prolonged overall survival and time to progression in patients with hepatocellular carcinoma. Here are presented the most effective MTTs which inhibit angiogenesis, the popular RAF/MAPK/ERK pathway, and stimulate apoptosis, and the possible combination of MTT and chemotherapy. Sorafenib, a multitarget tyrosine kinase inhibitor targeting both the RAF pathway and angiogenesis, is now registered in Poland.